Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Errata
You have accessRestricted Access

Erratum

JASN March 2019, 30 (3) 518; DOI: https://doi.org/10.1681/ASN.2019010051
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

CORRECTION

Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Kumar Derebail V, et al., and on behalf of the DUET Study Group: DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol 29: 2745–2754, 2018.

The authors wish to make a correction to Supplemental Table 6: Change in Diuretic Treatment During the Double-blind Period (Full Analysis Set). The table is not published in the main manuscript and is available in the supplemental material found at: http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2018010091/-/DCSupplemental.

The new table is below:

View this table:
  • View inline
  • View popup

The only change is a change in the number of “new or increased” loop diuretics from 1 (2.8%) to 2 (5.6%) which lessens the difference between the two groups. This change does not alter the conclusions from this table and does not impact any of the main findings or conclusions reported in the study.

  • Copyright © 2019 by the American Society of Nephrology
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 30 (3)
Journal of the American Society of Nephrology
Vol. 30, Issue 3
March 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Erratum
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Erratum
JASN Mar 2019, 30 (3) 518; DOI: 10.1681/ASN.2019010051

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Erratum
JASN Mar 2019, 30 (3) 518; DOI: 10.1681/ASN.2019010051
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • CORRECTION
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Erratum
  • Erratum
  • Erratum
Show more Errata

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire